UTI diagnostics designed for faster treatment decisions
Llusern Scientific develops rapid molecular diagnostic tests that support treatment decisions in near-patient clinical settings. Llusern’s first product is a 35 minute test that detects the bacteria in urine that cause the vast majority of all UTI cases.
This novel UTI test is run on Lodestar DX, Llusern’s proprietary platform technology. Lodestar DX is a small electronic reader that uses LAMP technology to analyse patient samples and provide fast, accurate measurements.
UTI diagnosis needs a faster answer
UTI is a common diagnostic challenge, but testing is slow, often uncertain or dependent on ageing central laboratory workflows. This often leaves treatment decisions being made before clear diagnostic information is available.
Llusern is focused on bringing faster molecular testing into real-world professional settings, where clearer information can support better decisions sooner.
The Lodestar UTI testing system brings molecular testing closer to the patient
The Lodestar UTI testing system is Llusern’s first product focus: a portable molecular analyser and test panel designed for near-patient use by professional users.
Lodestar detects six key UTI-causing bacterial pathogens from a small urine sample in just 35 minutes, allowing professional users access to clearer diagnostic information much sooner than lab culture testing and much more accurately than results provided by dipsticks.
Key product points
about Lodestar DXA focused product with scalable potential
Llusern is starting with a clear first use case: rapid UTI testing.
Lodestar DX creates a device-plus-consumables opportunity, with recurring test panel sales into a multitude of professional clinical settings.
Why it matters
Commercial PotentialBuilt for rapidly changing healthcare ecosystems
Lodestar DX is designed around speed, simplicity and portability.
It is ideal for use in decentralised healthcare settings because it eliminates the requirement for a traditional central laboratory UTI testing workflow.
Supporting points
Speak to the Team- Multiple publications and abstracts published
Built by people who understand diagnostics
Llusern brings together expertise across microbiology, molecular genetics, product development, regulatory compliance, urology, infectious disease and commercial diagnostics. The team combines scientific depth with practical product development and commercial focus.
Martyn Lewis
Dr Emma Hayhurst
Mr Bob Yang
Laurence Tisi
From award-winning innovation to a proven diagnostic product
Llusern has progressed from early innovation in antimicrobial resistance diagnostics to a market-facing product focused on rapid molecular UTI testing.
2023
Lodestar DX included in NICE Early Value Assessment. Llusern opens first office and lab at Cardiff Edge.
2024
Llusern opens dedicated production lab. Lodestar UTI testing system UKCA marked. Two peer-reviewed publications in JAC-AMR. Llusern runner-up in the Longitude Prize on AMR.
2025
ISO 13485 certification achieved. Study in elderly care settings to reduce antibiotic use. First sales into private urology practices.
2026
Abstracts presented at the European Association of Urology and at the American Urological Association annual congresses.
Today
Lodestar in daily use within private urology clinics and in NHS evaluations across the UK.
UTI diagnosis needs a faster answer
UTI is a common diagnostic challenge, but testing is slow, often uncertain or dependent on prescribed central laboratory workflows. This often leaves treatment decisions being made before clear diagnostic information is available.
Llusern is focused on bringing faster molecular testing into real-world professional settings, where clearer information can support better decisions sooner.
Testimonials
Lodestar DX represents an important step in making molecular UTI testing practical at the point where treatment decisions are made.
By bringing clearer diagnostic information closer to the patient, it can support faster, better-informed decisions in real-world professional settings.
As a spinal injury patient, new symptoms feel overwhelming. Lodestar gave me instant peace of mind. I drove two hours to Reading just to avoid the usual three day wait for culture results. It is brilliant.
For months, my NHS results came back as ‘mixed growth’ or ‘no significant growth’, which basically left me with no treatment plan and I felt fobbed off; it was such a waste of everyone’s time.
The Lodestar machine identified the specific three bacteria immediately. I wish I’d come here sooner; it’s the first time I’ve had a definitive answer and I’ve felt empowered.
News & Insights
- Awards
- Clinical Studies
- Appointments
Llusern bags a hat-trick at ICS 2026.
Two abstracts published in The Journal of Urology.
Llusern announces changes to Exec team and new NED
Start a conversation with Llusern
Llusern is developing treatment-directing diagnostics for high-volume healthcare challenges, starting with rapid molecular UTI testing. To learn more about the company, the product and the opportunity ahead, speak to the Llusern team.